Artiva Stock Based Compensation To Revenue from 2010 to 2024
| ARTV Stock | 10.40 0.22 2.07% |
Stock Based Compensation To Revenue | First Reported 2010-12-31 | Previous Quarter 0.2105876 | Current Value 0.2 | Quarterly Volatility 0.69500981 |
Check Artiva Biotherapeutics, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Artiva Biotherapeutics,'s main balance sheet or income statement drivers, such as Net Interest Income of 2.7 M, Interest Income of 2.7 M or Depreciation And Amortization of 2.4 M, as well as many indicators such as Price To Sales Ratio of 3.18, Dividend Yield of 0.0 or Days Sales Outstanding of 18.2. Artiva financial statements analysis is a perfect complement when working with Artiva Biotherapeutics, Valuation or Volatility modules.
Artiva | Stock Based Compensation To Revenue |
Latest Artiva Biotherapeutics,'s Stock Based Compensation To Revenue Growth Pattern
Below is the plot of the Stock Based Compensation To Revenue of Artiva Biotherapeutics, Common over the last few years. It is a metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards. Artiva Biotherapeutics,'s Stock Based Compensation To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Artiva Biotherapeutics,'s overall financial position and show how it may be relating to other accounts over time.
| Stock Based Compensation To Revenue | 10 Years Trend |
|
Stock Based Compensation To Revenue |
| Timeline |
Artiva Stock Based Compensation To Revenue Regression Statistics
| Arithmetic Mean | 1.84 | |
| Geometric Mean | 1.52 | |
| Coefficient Of Variation | 37.82 | |
| Mean Deviation | 0.50 | |
| Median | 2.15 | |
| Standard Deviation | 0.70 | |
| Sample Variance | 0.48 | |
| Range | 1.9513 | |
| R-Value | (0.68) | |
| Mean Square Error | 0.28 | |
| R-Squared | 0.46 | |
| Significance | 0.01 | |
| Slope | (0.10) | |
| Total Sum of Squares | 6.76 |
Artiva Stock Based Compensation To Revenue History
About Artiva Biotherapeutics, Financial Statements
Artiva Biotherapeutics, investors use historical fundamental indicators, such as Artiva Biotherapeutics,'s Stock Based Compensation To Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Artiva Biotherapeutics,. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Stock Based Compensation To Revenue | 0.21 | 0.20 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Artiva Stock Analysis
When running Artiva Biotherapeutics,'s price analysis, check to measure Artiva Biotherapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Artiva Biotherapeutics, is operating at the current time. Most of Artiva Biotherapeutics,'s value examination focuses on studying past and present price action to predict the probability of Artiva Biotherapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Artiva Biotherapeutics,'s price. Additionally, you may evaluate how the addition of Artiva Biotherapeutics, to your portfolios can decrease your overall portfolio volatility.